Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data

Stevens-Johnson syndrome (SJS) has been reported as a serious adverse effect in patients treated with vancomycin or linezolid, and there is currently a lack of real-world studies comparing specific differences in adverse effects of SJS. According to the FDA's Adverse Event Reporting System (FAE...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2022-04, Vol.13, p.872854-872854
Main Authors: Ni, Ming, Yin, Xue-Dong, Hu, Wen-Juan, Zeng, Na, Zhao, Bin, Li, Zhi-Ling
Format: Article
Language:English
Subjects:
adverse event reporting system
epidemiology
linezolid
Pharmacology
SJS
vancomycin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c465t-63c8970b3f5283cb0358e2ed584878bef8846c724ba9b97baaf40351a1d0c6d03
cites cdi_FETCH-LOGICAL-c465t-63c8970b3f5283cb0358e2ed584878bef8846c724ba9b97baaf40351a1d0c6d03
container_end_page 872854
container_issue
container_start_page 872854
container_title Frontiers in pharmacology
container_volume 13
creator Ni, Ming
Yin, Xue-Dong
Hu, Wen-Juan
Zeng, Na
Zhao, Bin
Li, Zhi-Ling
description Stevens-Johnson syndrome (SJS) has been reported as a serious adverse effect in patients treated with vancomycin or linezolid, and there is currently a lack of real-world studies comparing specific differences in adverse effects of SJS. According to the FDA's Adverse Event Reporting System (FAERS), from January 2004 to July 2021, the data of suspected SJS after the use of vancomycin and linezolid were analyzed by imbalance and Bayesian analysis. The onset time, fatality rate and hospitalization rate of vancomycin-associated SJS and linezolid-associated SJS were also investigated. 276 cases of vancomycin-related SJS reports and 63 cases of linezolid-related SJS reports were identified. These two drugs are more common in middle-aged patients (45-64 years) than other age groups, and less common in underage children (
doi_str_mv 10.3389/fphar.2022.872854
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_82e4191988ce47e6a72d416b36e8e4f6</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_82e4191988ce47e6a72d416b36e8e4f6</doaj_id><sourcerecordid>2665105095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-63c8970b3f5283cb0358e2ed584878bef8846c724ba9b97baaf40351a1d0c6d03</originalsourceid><addsrcrecordid>eNpVkUtvEzEURkcIRKvSH8AGeclmgt9js0CKCoWiIBDhsbQ8njuJi2MHexIUfj0zTalab2zZ3z2-uqeqnhM8Y0zpV_12bfOMYkpnqqFK8EfVKZGS1VoR-vje-aQ6L-Uaj4tpzSR_Wp0wIRqClT6t9ssB9hBL_TGtY0kRLQ-xy2kD6DKFkP74uEI_bHRpc3A-Ihs7tPAR_qbgu9dojr6CDfXPlEOH5tGGQ_EFpR59SWWoP9n8C4aJsNzlPfgQRhCgt3awz6onvQ0Fzm_3s-r75btvFx_qxef3VxfzRe24FEMtmVO6wS3rBVXMtZgJBRQ6obhqVAu9Uly6hvLW6lY3rbU9HzPEkg472WF2Vl0duV2y12ab_cbmg0nWm5uLlFfG5sG7AEZR4EQTrZQD3oC0De04kS2ToID3cmS9ObK2u3YDnYM4ZBseQB--RL82q7Q3GmuJqRgBL28BOf3eQRnMxhcH01gg7YqhUgqCBdZTlByjLqdSMvR33xBsJv3mRr-Z9Juj_rHmxf3-7ir-y2b_AITzrew</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2665105095</pqid></control><display><type>article</type><title>Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data</title><source>PubMed Central</source><creator>Ni, Ming ; Yin, Xue-Dong ; Hu, Wen-Juan ; Zeng, Na ; Zhao, Bin ; Li, Zhi-Ling</creator><creatorcontrib>Ni, Ming ; Yin, Xue-Dong ; Hu, Wen-Juan ; Zeng, Na ; Zhao, Bin ; Li, Zhi-Ling</creatorcontrib><description>Stevens-Johnson syndrome (SJS) has been reported as a serious adverse effect in patients treated with vancomycin or linezolid, and there is currently a lack of real-world studies comparing specific differences in adverse effects of SJS. According to the FDA's Adverse Event Reporting System (FAERS), from January 2004 to July 2021, the data of suspected SJS after the use of vancomycin and linezolid were analyzed by imbalance and Bayesian analysis. The onset time, fatality rate and hospitalization rate of vancomycin-associated SJS and linezolid-associated SJS were also investigated. 276 cases of vancomycin-related SJS reports and 63 cases of linezolid-related SJS reports were identified. These two drugs are more common in middle-aged patients (45-64 years) than other age groups, and less common in underage children (&lt;18). Among them, linezolid-related SJS is more common in middle-aged and elderly patients (45-74 years old) than other groups. Except for unspecified data, in vancomycin-associated SJS cases, there are more men than women (49.28% vs 43.84%), while in linezolid-associated SJS cases, the proportion of men and women is almost equal (44.44%). From the point of view of the areas where adverse reactions were reported, about 1/2 of the reports on Vancomycin-related SJS came from North America, and 1/3 of the reports came from Europe. The median onset time of Linezolid-related SJS was 5 days (interquartile range [IQR] 2-7.75), which was significantly earlier than that of Vancomycin-related SJS (12 days, IQR 4-20) (Mann-Whitney test, &lt; 0.0001). There were no significant differences in mortality and hospitalization rates after vancomycin and linezolid caused SJS. The analysis of faers data provides a comprehensive overview of the adverse reactions of SJS caused by the use of vancomycin and linezolid, and can warn clinical workers to timely intervene and continuously monitor the patients at risk of SJS when using such drugs.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2022.872854</identifier><identifier>PMID: 35571089</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>adverse event reporting system ; epidemiology ; linezolid ; Pharmacology ; SJS ; vancomycin</subject><ispartof>Frontiers in pharmacology, 2022-04, Vol.13, p.872854-872854</ispartof><rights>Copyright © 2022 Ni, Yin, Hu, Zeng, Zhao and Li.</rights><rights>Copyright © 2022 Ni, Yin, Hu, Zeng, Zhao and Li. 2022 Ni, Yin, Hu, Zeng, Zhao and Li</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-63c8970b3f5283cb0358e2ed584878bef8846c724ba9b97baaf40351a1d0c6d03</citedby><cites>FETCH-LOGICAL-c465t-63c8970b3f5283cb0358e2ed584878bef8846c724ba9b97baaf40351a1d0c6d03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096025/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096025/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35571089$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ni, Ming</creatorcontrib><creatorcontrib>Yin, Xue-Dong</creatorcontrib><creatorcontrib>Hu, Wen-Juan</creatorcontrib><creatorcontrib>Zeng, Na</creatorcontrib><creatorcontrib>Zhao, Bin</creatorcontrib><creatorcontrib>Li, Zhi-Ling</creatorcontrib><title>Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>Stevens-Johnson syndrome (SJS) has been reported as a serious adverse effect in patients treated with vancomycin or linezolid, and there is currently a lack of real-world studies comparing specific differences in adverse effects of SJS. According to the FDA's Adverse Event Reporting System (FAERS), from January 2004 to July 2021, the data of suspected SJS after the use of vancomycin and linezolid were analyzed by imbalance and Bayesian analysis. The onset time, fatality rate and hospitalization rate of vancomycin-associated SJS and linezolid-associated SJS were also investigated. 276 cases of vancomycin-related SJS reports and 63 cases of linezolid-related SJS reports were identified. These two drugs are more common in middle-aged patients (45-64 years) than other age groups, and less common in underage children (&lt;18). Among them, linezolid-related SJS is more common in middle-aged and elderly patients (45-74 years old) than other groups. Except for unspecified data, in vancomycin-associated SJS cases, there are more men than women (49.28% vs 43.84%), while in linezolid-associated SJS cases, the proportion of men and women is almost equal (44.44%). From the point of view of the areas where adverse reactions were reported, about 1/2 of the reports on Vancomycin-related SJS came from North America, and 1/3 of the reports came from Europe. The median onset time of Linezolid-related SJS was 5 days (interquartile range [IQR] 2-7.75), which was significantly earlier than that of Vancomycin-related SJS (12 days, IQR 4-20) (Mann-Whitney test, &lt; 0.0001). There were no significant differences in mortality and hospitalization rates after vancomycin and linezolid caused SJS. The analysis of faers data provides a comprehensive overview of the adverse reactions of SJS caused by the use of vancomycin and linezolid, and can warn clinical workers to timely intervene and continuously monitor the patients at risk of SJS when using such drugs.</description><subject>adverse event reporting system</subject><subject>epidemiology</subject><subject>linezolid</subject><subject>Pharmacology</subject><subject>SJS</subject><subject>vancomycin</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUtvEzEURkcIRKvSH8AGeclmgt9js0CKCoWiIBDhsbQ8njuJi2MHexIUfj0zTalab2zZ3z2-uqeqnhM8Y0zpV_12bfOMYkpnqqFK8EfVKZGS1VoR-vje-aQ6L-Uaj4tpzSR_Wp0wIRqClT6t9ssB9hBL_TGtY0kRLQ-xy2kD6DKFkP74uEI_bHRpc3A-Ihs7tPAR_qbgu9dojr6CDfXPlEOH5tGGQ_EFpR59SWWoP9n8C4aJsNzlPfgQRhCgt3awz6onvQ0Fzm_3s-r75btvFx_qxef3VxfzRe24FEMtmVO6wS3rBVXMtZgJBRQ6obhqVAu9Uly6hvLW6lY3rbU9HzPEkg472WF2Vl0duV2y12ab_cbmg0nWm5uLlFfG5sG7AEZR4EQTrZQD3oC0De04kS2ToID3cmS9ObK2u3YDnYM4ZBseQB--RL82q7Q3GmuJqRgBL28BOf3eQRnMxhcH01gg7YqhUgqCBdZTlByjLqdSMvR33xBsJv3mRr-Z9Juj_rHmxf3-7ir-y2b_AITzrew</recordid><startdate>20220428</startdate><enddate>20220428</enddate><creator>Ni, Ming</creator><creator>Yin, Xue-Dong</creator><creator>Hu, Wen-Juan</creator><creator>Zeng, Na</creator><creator>Zhao, Bin</creator><creator>Li, Zhi-Ling</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20220428</creationdate><title>Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data</title><author>Ni, Ming ; Yin, Xue-Dong ; Hu, Wen-Juan ; Zeng, Na ; Zhao, Bin ; Li, Zhi-Ling</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-63c8970b3f5283cb0358e2ed584878bef8846c724ba9b97baaf40351a1d0c6d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>adverse event reporting system</topic><topic>epidemiology</topic><topic>linezolid</topic><topic>Pharmacology</topic><topic>SJS</topic><topic>vancomycin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ni, Ming</creatorcontrib><creatorcontrib>Yin, Xue-Dong</creatorcontrib><creatorcontrib>Hu, Wen-Juan</creatorcontrib><creatorcontrib>Zeng, Na</creatorcontrib><creatorcontrib>Zhao, Bin</creatorcontrib><creatorcontrib>Li, Zhi-Ling</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ni, Ming</au><au>Yin, Xue-Dong</au><au>Hu, Wen-Juan</au><au>Zeng, Na</au><au>Zhao, Bin</au><au>Li, Zhi-Ling</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2022-04-28</date><risdate>2022</risdate><volume>13</volume><spage>872854</spage><epage>872854</epage><pages>872854-872854</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Stevens-Johnson syndrome (SJS) has been reported as a serious adverse effect in patients treated with vancomycin or linezolid, and there is currently a lack of real-world studies comparing specific differences in adverse effects of SJS. According to the FDA's Adverse Event Reporting System (FAERS), from January 2004 to July 2021, the data of suspected SJS after the use of vancomycin and linezolid were analyzed by imbalance and Bayesian analysis. The onset time, fatality rate and hospitalization rate of vancomycin-associated SJS and linezolid-associated SJS were also investigated. 276 cases of vancomycin-related SJS reports and 63 cases of linezolid-related SJS reports were identified. These two drugs are more common in middle-aged patients (45-64 years) than other age groups, and less common in underage children (&lt;18). Among them, linezolid-related SJS is more common in middle-aged and elderly patients (45-74 years old) than other groups. Except for unspecified data, in vancomycin-associated SJS cases, there are more men than women (49.28% vs 43.84%), while in linezolid-associated SJS cases, the proportion of men and women is almost equal (44.44%). From the point of view of the areas where adverse reactions were reported, about 1/2 of the reports on Vancomycin-related SJS came from North America, and 1/3 of the reports came from Europe. The median onset time of Linezolid-related SJS was 5 days (interquartile range [IQR] 2-7.75), which was significantly earlier than that of Vancomycin-related SJS (12 days, IQR 4-20) (Mann-Whitney test, &lt; 0.0001). There were no significant differences in mortality and hospitalization rates after vancomycin and linezolid caused SJS. The analysis of faers data provides a comprehensive overview of the adverse reactions of SJS caused by the use of vancomycin and linezolid, and can warn clinical workers to timely intervene and continuously monitor the patients at risk of SJS when using such drugs.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>35571089</pmid><doi>10.3389/fphar.2022.872854</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2022-04, Vol.13, p.872854-872854
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_82e4191988ce47e6a72d416b36e8e4f6
source PubMed Central
subjects adverse event reporting system
epidemiology
linezolid
Pharmacology
SJS
vancomycin
title Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T21%3A56%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stevens-Johnson%20Syndrome%20Following%20Vancomycin%20and%20Linezolid:%20A%20Real-World%20Analysis%20of%20Post-Marketing%20Surveillance%20Data&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Ni,%20Ming&rft.date=2022-04-28&rft.volume=13&rft.spage=872854&rft.epage=872854&rft.pages=872854-872854&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2022.872854&rft_dat=%3Cproquest_doaj_%3E2665105095%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-63c8970b3f5283cb0358e2ed584878bef8846c724ba9b97baaf40351a1d0c6d03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2665105095&rft_id=info:pmid/35571089&rfr_iscdi=true